ArticleNutrients2026
An Exploratory Study on Beneficial Effect of BE-FD-1 (Mineral-Enriched
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND/
objectivesType 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with insulin resistance, β-cell dysfunction, and systemic complications.
methodsIn this preliminary study, the metabolic effects of BE-FD-1, a water extract of
resultsBE-FD-1 at 500 mg/kg significantly reduced the oral glucose tolerance test area under the curve and fasting blood glucose levels, significantly restored serum insulin levels, and significantly decreased serum ALT, triglyceride, and total cholesterol levels relative to the HFD/STZ control group. Body weight gain and AST showed non-significant decreasing tendencies. Serum creatinine remained within the normal range, providing a preliminary safety signal that should be interpreted with caution given the absence of additional renal biomarkers and histopathological evaluation.
conclusionsThese exploratory findings suggest that BE-FD-1 may warrant further investigation as a candidate functional ingredient for T2DM-related metabolic dysfunction; however, larger studies with comprehensive phytochemical characterization, mechanistic validation, and broader safety evaluation are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.